Advertisement
Screener

Pediatrix Medical Group, Inc. (MD) Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest

2.8 / 5 stars · 68/120 Roast Me

Pediatrix Medical Group, Inc. Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest

Pediatrix Medical Group, Inc. (MD) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of -$99.07 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-20.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2025-02-20

  • Pediatrix Medical Group, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2023-12-31 was -$124.29M, a 617.86% decline year-over-year.
  • Pediatrix Medical Group, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2023-09-30 was $21.39M, a 25.75% decline year-over-year.
  • Pediatrix Medical Group, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2023-06-30 was $28.28M, a 7.88% decline year-over-year.
  • Pediatrix Medical Group, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2023-03-31 was $14.21M.
  • Pediatrix Medical Group, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2024 was -$99.07M.
  • Pediatrix Medical Group, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2023 was -$60.41M, a 196.55% decline from fiscal 2022.
  • Pediatrix Medical Group, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2022 was $62.56M, a 42.06% decline from fiscal 2021.
  • Pediatrix Medical Group, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2021 was $107.99M.
Period endIncome (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 monthIncome (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month as first filedIncome (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 monthIncome (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month as first filedIncome (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 monthIncome (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month as first filedIncome (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 monthIncome (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month as first filed
2024-12-31-$99.07M
10-K · filed 2025-02-20
2023-12-31-$124.29M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20
-$102.90M
derived: sum of 2 quarters · filed 2025-02-20
-$74.61M
derived: sum of 3 quarters · filed 2025-02-20
-$60.41M
10-K · filed 2025-02-20
2023-09-30$21.39M
10-Q · filed 2023-11-02
$49.67M
derived: sum of 2 quarters · filed 2023-11-02
$63.88M
10-Q · filed 2023-11-02
$87.88M
derived: sum of 4 quarters · filed 2025-02-20
2023-06-30$28.28M
10-Q · filed 2023-08-03
$42.49M
10-Q · filed 2023-08-03
$66.49M
derived: sum of 3 quarters · filed 2025-02-20
$95.30M
derived: sum of 4 quarters · filed 2025-02-20
2023-03-31$14.21M
10-Q · filed 2023-05-02
$38.21M
derived: sum of 2 quarters · filed 2025-02-20
$67.01M
derived: sum of 3 quarters · filed 2025-02-20
$97.72M
derived: sum of 4 quarters · filed 2025-02-20
2022-12-31$24.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20
$52.81M
derived: sum of 2 quarters · filed 2025-02-20
$83.51M
derived: sum of 3 quarters · filed 2025-02-20
$62.56M
10-K · filed 2025-02-20
2022-09-30$28.81M
10-Q · filed 2023-11-02
$59.51M
derived: sum of 2 quarters · filed 2023-11-02
$38.56M
10-Q · filed 2023-11-02
$78.84M
derived: sum of 4 quarters · filed 2024-02-20
2022-06-30$30.70M
10-Q · filed 2023-08-03
$9.76M
10-Q · filed 2023-08-03
$50.03M
derived: sum of 3 quarters · filed 2024-02-20
$81.87M
derived: sum of 4 quarters · filed 2024-02-20
2022-03-31-$20.95M
10-Q · filed 2023-05-02
$19.33M
derived: sum of 2 quarters · filed 2024-02-20
$51.17M
derived: sum of 3 quarters · filed 2024-02-20
$81.70M
derived: sum of 4 quarters · filed 2024-02-20
2021-12-31$40.28M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20
$72.12M
derived: sum of 2 quarters · filed 2024-02-20
$102.64M
derived: sum of 3 quarters · filed 2024-02-20
$107.99M
10-K · filed 2024-02-20
2021-09-30$31.84M
10-Q · filed 2022-11-03
$62.37M
derived: sum of 2 quarters · filed 2022-11-03
$67.71M
10-Q · filed 2022-11-03
$72.20M
derived: sum of 4 quarters · filed 2022-11-03
2021-06-30$30.53M
10-Q · filed 2022-08-04
$35.87M
10-Q · filed 2022-08-04
$40.36M
derived: sum of 3 quarters · filed 2022-08-04
$37.71M
derived: sum of 4 quarters · filed 2022-08-04
2021-03-31$5.34M
10-Q · filed 2022-04-28
$9.83M
derived: sum of 2 quarters · filed 2022-04-28
$7.18M
derived: sum of 3 quarters · filed 2022-04-28
$14.26M
derived: sum of 4 quarters · filed 2022-04-28
2020-12-31$4.49M
10-K · filed 2021-02-18
$1.83M
derived: sum of 2 quarters · filed 2021-10-28
$8.92M
derived: sum of 3 quarters · filed 2021-10-28
-$9.58M
10-K · filed 2023-02-17
2020-09-30-$2.65M
10-Q · filed 2021-10-28
$4.43M
derived: sum of 2 quarters · filed 2021-10-28
-$14.07M
10-Q · filed 2021-10-28
-$4.14M
derived: sum of 4 quarters · filed 2021-10-28
2020-06-30$7.08M
10-Q · filed 2021-08-06
$7.60M
10-Q · filed 2020-07-30
-$11.41M
10-Q · filed 2021-08-06
-$6.15M
10-Q · filed 2020-07-30
-$1.49M
derived: sum of 3 quarters · filed 2021-08-06
$11.40M
derived: sum of 4 quarters · filed 2021-08-06
2020-03-31-$18.50M
10-Q · filed 2021-05-07
-$16.11M
10-Q · filed 2020-05-07
-$8.57M
derived: sum of 2 quarters · filed 2021-05-07
$4.32M
derived: sum of 3 quarters · filed 2021-05-07
$10.84M
derived: sum of 4 quarters · filed 2021-05-07
2019-12-31$9.93M
10-K · filed 2021-02-18
$32.98M
10-K · filed 2020-02-20
$22.81M
derived: sum of 2 quarters · filed 2021-02-18
$29.34M
derived: sum of 3 quarters · filed 2021-02-18
$42.21M
10-K · filed 2022-02-17
-$1.15B
10-K · filed 2020-02-20
2019-09-30$12.89M
10-K · filed 2021-02-18
-$1.26B
10-Q · filed 2019-11-01
$19.41M
derived: sum of 2 quarters · filed 2021-02-18
$32.28M
10-Q · filed 2020-11-06
-$1.18B
10-Q · filed 2019-11-01
$93.94M
derived: sum of 4 quarters · filed 2021-02-18
2019-06-30$6.53M
10-K · filed 2021-02-18
$35.52M
10-Q · filed 2019-08-01
$42.59M
10-Q · filed 2020-07-30
$77.17M
10-Q · filed 2019-08-01
$81.06M
derived: sum of 3 quarters · filed 2021-02-18
$143.22M
derived: sum of 4 quarters · filed 2021-02-18
2019-03-31$12.87M
10-K · filed 2021-02-18
$41.65M
10-Q · filed 2019-05-02
$74.53M
derived: sum of 2 quarters · filed 2021-02-18
$136.70M
derived: sum of 3 quarters · filed 2021-02-18
$211.47M
derived: sum of 4 quarters · filed 2021-02-18
2018-12-31$61.66M
10-K · filed 2020-02-20
$123.83M
derived: sum of 2 quarters · filed 2020-02-20
$198.60M
derived: sum of 3 quarters · filed 2020-02-20
$121.51M
10-K · filed 2021-02-18
$258.61M
10-K · filed 2020-02-20
2018-09-30$62.17M
10-K · filed 2020-02-20
$136.94M
derived: sum of 2 quarters · filed 2020-02-20
$196.95M
10-Q · filed 2019-11-01
2018-06-30$74.78M
10-K · filed 2020-02-20
$134.78M
10-Q · filed 2019-08-01
2018-03-31$60.01M
10-K · filed 2020-02-20
2017-12-31$305.44M
10-K · filed 2020-02-20

Similar stocks

Stock NameCountryMarket CapPE Ratio
Encompass Health Corp (EHC)United States$12.039B16.15